InMed Pharmaceuticals specializes in developing cannabinoid-based therapeutics to treat serious diseases with high unmet medical needs.
InMed presents Phase 2 clinical study results at 12th World Congress on Itch
At the 12th World Congress on Itch (WCI), held in Miami on November 5-7, 2023, InMed’s Senior VP, Clinical and Regulatory Affairs, Alexandra Mancini presented